Life Technologies has begun clinical trials to prove the safety and effectiveness of sequence-based typing on its 3500 Dx Genetic Analyzer for analyzing the Human Leukocyte Antigen region and plans to apply for 510(k) clearance of the SBT platform, the company said this week.

An undisclosed clinical research organization will oversee the clinical trials at several independent, accredited HLA typing laboratories in the US. These labs will use the 3500 Dx Genetic Analyzer, SeCore kits, and uType Dx software to analyze six gene regions of the HLA system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.